603590 康辰药业
交易中 10-14 14:56:24
资讯
新帖
简况
康辰药业：第五届董事会第七次会议决议公告
同花顺 · 10-13 21:03
康辰药业：第五届董事会第七次会议决议公告
康辰药业：关于召开2026年第二次临时股东会的通知
同花顺 · 10-13 21:03
康辰药业：关于召开2026年第二次临时股东会的通知
康辰药业（603590）10月13日主力资金净卖出388.08万元
证券之星 · 10-13 15:26
康辰药业（603590）10月13日主力资金净卖出388.08万元
股市必读：康辰药业新发布《康辰药业关于股份回购进展公告》
证券之星 · 10-12 01:30
股市必读：康辰药业新发布《康辰药业关于股份回购进展公告》
康辰药业（603590）披露股份回购进展公告，10月9日股价下跌0.67%
证券之星 · 10-09
康辰药业（603590）披露股份回购进展公告，10月9日股价下跌0.67%
康辰药业：已累计回购占总1.24%公司股份 支付总金额7843万元
同花顺 · 10-09
康辰药业：已累计回购占总1.24%公司股份 支付总金额7843万元
康辰药业涨10.00%，太平洋三周前给出“买入”评级
证券之星 · 09-30
康辰药业涨10.00%，太平洋三周前给出“买入”评级
异动快报：康辰药业（603590）9月30日9点55分触及涨停板
证券之星 · 09-30
异动快报：康辰药业（603590）9月30日9点55分触及涨停板
康辰药业（603590）披露召开2026年半年度业绩说明会公告，9月29日股价上涨0.1%
证券之星 · 09-29
康辰药业（603590）披露召开2026年半年度业绩说明会公告，9月29日股价上涨0.1%
康辰药业（603590）披露涉及仲裁结果的公告，9月28日股价下跌0.75%
证券之星 · 09-28
康辰药业（603590）披露涉及仲裁结果的公告，9月28日股价下跌0.75%
股市必读：康辰药业新发布《康辰药业关于2026年限制性股票激励计划首次授予结果公告》
证券之星 · 09-28
股市必读：康辰药业新发布《康辰药业关于2026年限制性股票激励计划首次授予结果公告》
康辰药业（603590）披露2026年限制性股票激励计划首次授予结果公告，9月24日股价下跌1.8%
证券之星 · 09-24
康辰药业（603590）披露2026年限制性股票激励计划首次授予结果公告，9月24日股价下跌1.8%
康辰药业：9月22日董事牛战旗、黄憗增持股份合计35万股
证券之星 · 09-23
康辰药业：9月22日董事牛战旗、黄憗增持股份合计35万股
康辰药业：注射用尖吻蝮蛇血凝酶获新兽药注册证书
同花顺 · 09-15
康辰药业：注射用尖吻蝮蛇血凝酶获新兽药注册证书
康辰药业获得发明专利授权：“靶向PD-L1和FasL的融合蛋白、核苷酸序列及其应用”
证券之星 · 09-12
康辰药业获得发明专利授权：“靶向PD-L1和FasL的融合蛋白、核苷酸序列及其应用”
中航证券：给予康辰药业买入评级
证券之星 · 09-06
中航证券：给予康辰药业买入评级
每周股票复盘：康辰药业（603590）回购金额达7843万占比1.26%
证券之星 · 09-06
每周股票复盘：康辰药业（603590）回购金额达7843万占比1.26%
康辰药业（603590）18.5万股限售股将于9月4日解禁，占总股本0.12%
证券之星 · 09-04
康辰药业（603590）18.5万股限售股将于9月4日解禁，占总股本0.12%
股市必读：康辰药业新发布《康辰药业关于股份回购进展公告》
证券之星 · 09-04
股市必读：康辰药业新发布《康辰药业关于股份回购进展公告》
康辰药业（603590）披露股份回购进展公告，9月2日股价下跌1.84%
证券之星 · 09-02
康辰药业（603590）披露股份回购进展公告，9月2日股价下跌1.84%
加载更多
公司概况
公司名称：
北京康辰药业股份有限公司
所属行业：
医药制造业
上市日期：
2018-08-27
主营业务：
北京康辰药业股份有限公司的主营业务是创新药研发、生产与销售。公司的主要产品是注射用尖吻蝮蛇血凝酶、鲑降钙素注射液、鲑降钙素鼻用喷雾剂。
发行价格：
24.34
{"stockData":{"symbol":"603590","market":"SH","secType":"STK","nameCN":"康辰药业","latestPrice":28.01,"timestamp":1791960984000,"preClose":29.2,"halted":0,"volume":3438714,"delay":0,"changeRate":-0.0408,"floatShares":159000000,"shares":161000000,"eps":1.0581,"marketStatus":"交易中","change":-1.19,"latestTime":"10-14 14:56:24","open":29.02,"high":29.09,"low":28,"amount":97461300,"amplitude":0.0373,"askPrice":28.01,"askSize":36,"bidPrice":28,"bidSize":606,"shortable":0,"etf":0,"ttmEps":1.0581,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1791961200000},"marketStatusCode":2,"adr":0,"adjPreClose":29.2,"symbolType":"stock","openAndCloseTimeList":[[1791941400000,1791948600000],[1791954000000,1791961200000]],"highLimit":32.12,"lowLimit":26.28,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":161285477,"isCdr":false,"pbRate":1.48,"roa":"--","peRate":26.471978,"roe":"2.98%","epsLYR":1.05,"committee":0.53125,"marketValue":4518000000,"turnoverRate":0.0216,"status":1,"floatMarketCap":4454000000},"requestUrl":"/m/hq/s/603590/","defaultTab":"news","newsList":[{"id":"2675369357","title":"康辰药业：第五届董事会第七次会议决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2675369357","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675369357?lang=zh_cn&edition=full","pubTime":"2026-10-13 21:03","pubTimestamp":1791896580,"startTime":"0","endTime":"0","summary":" 证券日报网讯 10月13日，康辰药业发布公告称，公司于2026年10月13日召开第五届董事会第七次会议，审议通过《关于回购注销部分激励对象已获授但尚未解除限售的 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261013/c680653754.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261013/c680653754.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675357363","title":"康辰药业：关于召开2026年第二次临时股东会的通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2675357363","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675357363?lang=zh_cn&edition=full","pubTime":"2026-10-13 21:03","pubTimestamp":1791896580,"startTime":"0","endTime":"0","summary":" 证券日报网讯 10月13日，康辰药业发布公告称，公司将于2026年10月29日召开2026年第二次临时股东会。 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261013/c680653794.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261013/c680653794.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675396873","title":"康辰药业（603590）10月13日主力资金净卖出388.08万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675396873","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675396873?lang=zh_cn&edition=full","pubTime":"2026-10-13 15:26","pubTimestamp":1791876371,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，康辰药业报收于29.2元，下跌2.73%，换手率2.65%，成交量4.22万手，成交额1.23亿元。康辰药业主营业务：公司是一家以创新药研发为核心、以临床需求为导向,集研发、生产和销售于一体的创新型制药企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300020188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674437548","title":"股市必读：康辰药业新发布《康辰药业关于股份回购进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674437548","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674437548?lang=zh_cn&edition=full","pubTime":"2026-10-12 01:30","pubTimestamp":1791739829,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘，康辰药业报收于30.98元，下跌0.67%，换手率3.65%，成交量5.8万手，成交额1.77亿元。公司公告汇总康辰药业关于股份回购进展公告北京康辰药业股份有限公司于2025年10月15日召开董事会审议通过回购股份方案，拟以集中竞价交易方式回购股份，用于员工持股计划或股权激励。截至2026年9月30日，已累计回购1,998,804股，占公司总股本的1.24%，回购最高价为51.40元/股，最低价为28.36元/股，已支付总金额78,433,881.08元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200000478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674185055","title":"康辰药业（603590）披露股份回购进展公告，10月9日股价下跌0.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674185055","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674185055?lang=zh_cn&edition=full","pubTime":"2026-10-09 22:14","pubTimestamp":1791555271,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘，康辰药业报收于30.98元，较前一交易日下跌0.67%，最新总市值为49.97亿元。近日，康辰药业发布《关于股份回购进展公告》。公告显示，公司于2025年10月15日召开董事会审议通过回购股份方案，拟以集中竞价交易方式回购股份，用于员工持股计划或股权激励。截至2026年9月30日，已累计回购1,998,804股，占公司总股本的1.24%，回购最高价为51.40元/股，最低价为28.36元/股，已支付总金额78,433,881.08元。本次回购符合相关法规及公司方案要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900038195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674830369","title":"康辰药业：已累计回购占总1.24%公司股份 支付总金额7843万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674830369","media":"同花顺","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674830369?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:08","pubTimestamp":1791536880,"startTime":"0","endTime":"0","summary":"上证智讯10月9日晚间，康辰药业发布公告称，截至2026年9月30日，公司已累计回购股份199.88万股，占本公告披露时公司总股本的比例为1.24%，购买的最高价为51.40元/股、最低价为28.36元/股， ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261009/c680531711.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261009/c680531711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671921274","title":"康辰药业涨10.00%，太平洋三周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2671921274","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671921274?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:33","pubTimestamp":1790757230,"startTime":"0","endTime":"0","summary":"今日康辰药业（603590）涨10.00%，收盘报32.11元。2026年9月8日，太平洋研究员谭紫媚,张懿发布了对康辰药业的研报《康辰药业：重点产品保持稳健增长，创新管线形成梯度布局》，该研报对康辰药业给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为61.07%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为长江证券的刘长洪。康辰药业（603590）个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000025771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","601099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671221583","title":"异动快报：康辰药业（603590）9月30日9点55分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2671221583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671221583?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:01","pubTimestamp":1790733664,"startTime":"0","endTime":"0","summary":"证券之星9月30日盘中消息，9点55分康辰药业（603590）触及涨停板。其所属行业生物制品目前上涨。领涨股为康希诺。该股为肿瘤疫苗，创新药，医药概念热股，当日肿瘤疫苗概念上涨4.66%，创新药概念上涨2.49%，医药概念上涨2.34%。9月29日的资金流向数据方面，主力资金净流出64.98万元，占总成交额1.42%，游资资金净流出297.9万元，占总成交额6.52%，散户资金净流入362.88万元，占总成交额7.95%。近5日资金流向一览见下表：康辰药业主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000010323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671248454","title":"康辰药业（603590）披露召开2026年半年度业绩说明会公告，9月29日股价上涨0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671248454","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671248454?lang=zh_cn&edition=full","pubTime":"2026-09-29 22:33","pubTimestamp":1790692396,"startTime":"0","endTime":"0","summary":"截至2026年9月29日收盘，康辰药业报收于29.19元，较前一交易日上涨0.1%，最新总市值为47.08亿元。该股当日开盘28.87元，最高29.77元，最低28.72元，成交额达4565.59万元，换手率为0.98%。近日，康辰药业发布《关于召开2026年半年度业绩说明会的公告》。公告显示，公司将于2026年10月15日16:00-17:00通过上证路演中心网络互动方式召开2026年半年度业绩说明会，介绍公司半年度经营成果及财务状况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900040594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670223504","title":"康辰药业（603590）披露涉及仲裁结果的公告，9月28日股价下跌0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670223504","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670223504?lang=zh_cn&edition=full","pubTime":"2026-09-28 17:56","pubTimestamp":1790589400,"startTime":"0","endTime":"0","summary":"截至2026年9月28日收盘，康辰药业报收于29.16元，较前一交易日下跌0.75%，最新总市值为47.03亿元。近日，康辰药业发布《关于涉及仲裁结果的公告》。公司已收到两份终局裁决书，裁定五名被申请人连带支付违约金、相关费用及资金占用费等，合计金额约为16,810.01万元。裁决已生效，但被申请人尚未履行付款义务，款项回收存在不确定性。目前公司无其他应披露未披露的重大诉讼或仲裁事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800023895.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670409005","title":"股市必读：康辰药业新发布《康辰药业关于2026年限制性股票激励计划首次授予结果公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670409005","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670409005?lang=zh_cn&edition=full","pubTime":"2026-09-28 02:42","pubTimestamp":1790534532,"startTime":"0","endTime":"0","summary":"公司公告汇总：康辰药业完成2026年限制性股票激励计划首次授予登记，授予227.50万股，总股本增至161,285,477股。公司公告汇总康辰药业关于2026年限制性股票激励计划首次授予结果公告北京康辰药业股份有限公司已完成2026年限制性股票激励计划首次授予登记工作，授予日为2026年8月6日，登记日为2026年9月22日，授予数量为227.50万股，授予价格为15.40元/股，共有63名激励对象获授。裁决已生效，但被申请人尚未履行付款义务，款项回收存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800001350.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669469194","title":"康辰药业（603590）披露2026年限制性股票激励计划首次授予结果公告，9月24日股价下跌1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669469194","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669469194?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:48","pubTimestamp":1790243309,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，康辰药业报收于29.38元，较前一交易日下跌1.8%，最新总市值为47.39亿元。康辰药业于近日披露《关于2026年限制性股票激励计划首次授予结果公告》。公告显示，公司已完成2026年限制性股票激励计划首次授予登记工作，授予日为2026年8月6日，登记日为2026年9月22日，授予数量为227.50万股，授予价格为15.40元/股，共有63名激励对象获授。限制性股票限售期为12个月和24个月，分两期各解除限售50%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400031131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669483232","title":"康辰药业：9月22日董事牛战旗、黄憗增持股份合计35万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669483232","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669483232?lang=zh_cn&edition=full","pubTime":"2026-09-23 20:01","pubTimestamp":1790164899,"startTime":"0","endTime":"0","summary":"证券之星消息，根据9月23日市场公开信息、上市公司公告及交易所披露数据整理，康辰药业（603590）最新董监高及相关人员股份变动情况：2026年9月22日公司董事,高级管理人员牛战旗、董事黄憗共增持公司股份35.0万股，占公司总股本为0.2201%。变动期间公司股价上涨0.27%，9月22日当日收盘报29.96元。康辰药业近半年内的董监高及核心技术人员增减持详情如下：康辰药业的高管列表及最新持股情况如下：该股最近90天内共有7家机构给出评级，买入评级5家，增持评级2家。本文数据来源于上海证券交易所信息披露、康辰药业公告，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300036786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667764992","title":"康辰药业：注射用尖吻蝮蛇血凝酶获新兽药注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2667764992","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667764992?lang=zh_cn&edition=full","pubTime":"2026-09-15 18:48","pubTimestamp":1789469280,"startTime":"0","endTime":"0","summary":"每经AI快讯，9月15日，康辰药业(603590.SH)公告称，公司及全资子公司北京爱欣湾医药科技有限公司联合申报的“注射用尖吻蝮蛇血凝酶”获农业农村部批准为新兽药，用于犬手术出血的止血。该品 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260915/c679931650.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260915/c679931650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571627","title":"康辰药业获得发明专利授权：“靶向PD-L1和FasL的融合蛋白、核苷酸序列及其应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571627","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666571627?lang=zh_cn&edition=full","pubTime":"2026-09-12 03:48","pubTimestamp":1789156105,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示康辰药业新获得一项发明专利授权，专利名为“靶向PD-L1和FasL的融合蛋白、核苷酸序列及其应用”，专利申请号为CN202111162221.5，授权日为2026年9月11日。本发明的融合蛋白同时包括能够结合PDL1的部分和特异性结合FasL的部分，这种双功能融合蛋白分子能够产生协同作用，发挥高效的抗肿瘤的作用。今年以来康辰药业新获得专利授权3个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091200004417.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665302369","title":"中航证券：给予康辰药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2665302369","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665302369?lang=zh_cn&edition=full","pubTime":"2026-09-06 09:55","pubTimestamp":1788659714,"startTime":"0","endTime":"0","summary":"中航证券有限公司李蔚近期对康辰药业进行研究并发布了研究报告《核心产品提供长期支撑，研发管线多点突破》，给予康辰药业买入评级。单季度来看，2026年第二季度营业收入环比增长15.38%，呈现季节性回升态势。 风险提示：药品研发不及预期风险、政策风险、市场竞争加剧风险最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级3家，增持评级2家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600002630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665663403","title":"每周股票复盘：康辰药业（603590）回购金额达7843万占比1.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665663403","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665663403?lang=zh_cn&edition=full","pubTime":"2026-09-06 03:18","pubTimestamp":1788635893,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，康辰药业报收于30.03元，较上周的30.75元下跌2.34%。本周，康辰药业9月1日盘中最高价报30.67元。本周关注点公司公告汇总：已累计回购1,998,804股，占公司总股本的1.26%公司公告汇总：回购已支付总金额78,433,881.08元公司公告汇总：回购最高价为51.40元/股，最低价为28.36元/股公司公告汇总康辰药业关于股份回购进展公告：截至2026年8月31日，已累计回购1,998,804股，占公司总股本的1.26%，支付总金额78,433,881.08元，回购最高价为51.40元/股，最低价为28.36元/股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600001093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664807768","title":"康辰药业（603590）18.5万股限售股将于9月4日解禁，占总股本0.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664807768","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664807768?lang=zh_cn&edition=full","pubTime":"2026-09-04 08:12","pubTimestamp":1788480732,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，康辰药业于9月4日将有18.5万股限售股份解禁，为公司股权激励限售股份，占公司总股本0.12%。最近一年内，该股累计解禁98.6万股，占总股本的0.62%。本次解禁后，公司还有60.2万股限售股份，占总股本0.38%。康辰药业主营业务：公司是一家以创新药研发为核心、以临床需求为导向,集研发、生产和销售于一体的创新型制药企业。本文数据来源于康辰药业公告，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400007424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664806024","title":"股市必读：康辰药业新发布《康辰药业关于股份回购进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664806024","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664806024?lang=zh_cn&edition=full","pubTime":"2026-09-04 02:41","pubTimestamp":1788460869,"startTime":"0","endTime":"0","summary":"截至2026年9月3日收盘，康辰药业报收于30.15元，上涨0.74%，换手率0.88%，成交量1.39万手，成交额4190.48万元。公司公告汇总：截至2026年8月31日，康辰药业已累计回购1,998,804股，占总股本1.26%，支付金额78,433,881.08元。公司公告汇总康辰药业关于股份回购进展公告北京康辰药业股份有限公司于2025年10月15日召开董事会审议通过回购股份方案，拟以集中竞价交易方式回购股份，用于员工持股计划或股权激励。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400002780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664810260","title":"康辰药业（603590）披露股份回购进展公告，9月2日股价下跌1.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664810260","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664810260?lang=zh_cn&edition=full","pubTime":"2026-09-02 23:03","pubTimestamp":1788361400,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，康辰药业报收于29.93元，较前一交易日下跌1.84%，最新总市值为47.59亿元。该股当日开盘30.32元，最高30.45元，最低29.87元，成交额达6889.04万元，换手率为1.45%。近日，康辰药业发布《关于股份回购进展公告》。公告显示，公司于2025年10月15日召开董事会审议通过回购股份方案，拟以集中竞价交易方式回购股份，用于员工持股计划或股权激励。本次回购符合相关法规及公司方案要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200043468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791960988638,"stockEarnings":[{"period":"1week","weight":-0.0906},{"period":"1month","weight":0.0278},{"period":"3month","weight":-0.2078},{"period":"6month","weight":-0.242},{"period":"1year","weight":-0.4056},{"period":"ytd","weight":-0.2574}],"compareEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":-0.0224},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0628},{"period":"1year","weight":-0.0228},{"period":"ytd","weight":-0.0423}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京康辰药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15291人(较上一季度增加0.33%)","perCapita":"10398股","listingDate":"2018-08-27","address":"北京市密云区经济开发区兴盛南路11号","registeredCapital":"16128万元","survey":" 北京康辰药业股份有限公司的主营业务是创新药研发、生产与销售。公司的主要产品是注射用尖吻蝮蛇血凝酶、鲑降钙素注射液、鲑降钙素鼻用喷雾剂。","listedPrice":24.34},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康辰药业(603590)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康辰药业(603590)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康辰药业,603590,康辰药业股票,康辰药业股票老虎,康辰药业股票老虎国际,康辰药业行情,康辰药业股票行情,康辰药业股价,康辰药业股市,康辰药业股票价格,康辰药业股票交易,康辰药业股票购买,康辰药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康辰药业(603590)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康辰药业(603590)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}